EGFR and non-small cell lung carcinoma: An in vitro experiment in an NSCLC mouse model (L858R/T790M/C797S triple mutations) showed that EAI045 (fourth-generation EGFR-TKI), combined with cetuximab, could effectively prevent EGFR dimerization.